Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant...

Area of Science:

• Oncology
• Nuclear Medicine
• Prostate Cancer Research

Background:

• Metastatic castrate-resistant prostate cancer (mCRPC) is an advanced stage of prostate cancer.
• Radium 223 (Ra-223) dichloride is an alpha-emitting therapeutic agent used for mCRPC.
• Predicting treatment outcomes is crucial for optimizing patient management.

Purpose of the Study:

• To analyze treatment outcomes in mCRPC patients receiving Ra-223.
• To identify factors predicting overall survival and treatment completion.

Main Methods:

• Retrospective cohort study of 189 mCRPC patients treated with Ra-223.
• Data collected between March 2014 and April 2017.
• Multivariable analysis to assess predictors of survival and treatment completion.

Main Results:

• Median overall survival was 10.5 months.
• Patients completing 5-6 cycles of Ra-223 survived longer (18.6 months).
• Predictors of overall survival included younger age, completion of Ra-223 cycles, lower alkaline phosphatase, and lower neutrophil-to-lymphocyte ratio.

Conclusions:

• Younger age, completing Ra-223 treatment, lower alkaline phosphatase, and neutrophil-to-lymphocyte ratio are associated with improved overall survival.
• Good performance status and higher baseline hemoglobin predict completion of 5-6 Ra-223 cycles.
• Neutrophil-to-lymphocyte ratio is identified as a novel independent predictor of survival in Ra-223 treated mCRPC patients.